Taylor & Francis Group
Browse
1/1
5 files

Letter to the editor: switching treatment to lamivudine plus boosted atazanavir or darunavir in virologically suppressed HIV-infected patients – evidence from a large observational cohort

dataset
posted on 2019-04-10, 07:02 authored by D. F. Bavaro, D. Di Carlo, P. Zuccalà, F. Bai, F. Incardona, A. Battisti, S. Giachè, E. Salomoni, R. Gagliardini, S. Di Giambenedetto, M. Pecorari, M. Zazzi, A. De Luca, A. Bezenchek, S. Lo Caputo
Letter to the editor: switching treatment to lamivudine plus boosted atazanavir or darunavir in virologically suppressed HIV-infected patients – evidence from a large observational cohort

Funding

This study has been funded within the ARCA Mentor School by unconditional educational grants from: ViiV Healthcare, GILEAD Sciences, Janssen-Cilag, Hologic, Merck Sharp and Dohme, Bristol-Myers Squibb, Siemens Healthineers

History